Progress on the research and development of inactivated EV71 whole-virus vaccines.
about
Development of Novel Vaccines against Enterovirus-71Epidemiological Research on Hand, Foot, and Mouth Disease in Mainland ChinaRecent Progress towards Novel EV71 Anti-Therapeutics and VaccinesInactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic MouseAttenuation of human enterovirus 71 high-replication-fidelity variants in AG129 miceRecombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in miceAn inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice.Enterovirus 71 infection impairs the reproductive capacity of female miceIdentification of luteolin as enterovirus 71 and coxsackievirus A16 inhibitors through reporter viruses and cell viability-based screeningHow to understand the efficacy measurements for enterovirus type 71 vaccine?History of vaccinationEV71 vaccine, an invaluable gift for children.Seroprevalence of human enterovirus 71 and coxsackievirus A16 in Guangdong, China, in pre- and post-2010 HFMD epidemic period.Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central ChinaBroad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn miceShort-Fragment DNA Residue from Vaccine Purification Processes Promotes Immune Response to the New Inactivated EV71 Vaccine by Upregulating TLR9 mRNACurcumin inhibits the replication of enterovirus 71 in vitroSingle Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral EntryEngineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game.Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial.Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine.Comprehensive safety assessment of a human inactivated diploid enterovirus 71 vaccine based on a phase III clinical trialEpidemiology and seroepidemiology of human enterovirus 71 among Thai populations.Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials.Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine.Enterovirus71 virus-like particles produced from insect cells and purified by multistep chromatography elicit strong humoral immune responses in mice.Characterization of human enterovirus71 virus-like particles used for vaccine antigens.Meteorological factors affect the hand, foot, and mouth disease epidemic in Qingdao, China, 2007-2014.Determinants of EV71 immunogenicity and protection against lethal challenge in a mouse model.Hand, Foot and Mouth Disease in West Bengal, India: A Preliminary Report on Clinicovirological Trend over 3 Successive Years (2013-2015)Characterization of the enterovirus 71 VP1 protein as a vaccine candidate.Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice.
P2860
Q26771247-F775E5DC-17A5-41A1-BE67-77072858160DQ26774357-EB1701BB-15E8-45A0-A972-732001C52DE9Q26775734-60678826-EEDA-48D3-8D52-F0DF0786512EQ27321616-744F3400-C371-4985-9F51-82B10C8040AEQ33602804-8F990A2E-2718-4DA3-9531-0A43821DCDB0Q33646488-59B18BC0-4818-44EB-9482-89A8E16548B7Q33724967-972455F6-22B8-4C28-8B4E-D7433D5D602AQ33846967-1D3857B7-322D-40ED-A69F-F7C34F5E68D1Q33963444-1FA76523-AD34-4863-9D40-9FBEE6437EF6Q34033907-524DDF64-82D4-4523-B236-3440B03B3B9EQ34119899-82CE2197-F989-484C-9280-A797B2BE5292Q34540559-DDCCECF3-27DD-4306-9837-DB8DE66826F2Q35063743-E4A35FF6-3A6E-4EA2-81A9-84AF38F37C24Q35158936-6C38B93C-6D49-426B-9785-C8736C4E47F9Q35689929-43ED437D-055C-400B-8ECC-E3ACC7DF7DD4Q35991169-CA1BA443-74DA-4E2D-B06A-F0516BEBAA81Q36237565-95109897-EB7B-4CDD-915E-D0633B857B82Q36281127-0F500CB1-F7CE-4EA7-9F4B-A7E3F6B61270Q36523940-D5060995-61D9-425D-8B85-8D5D0A271875Q36977606-E99E661C-8096-4C4B-ACC9-E9B52E741925Q36978457-9B27A8EB-E33F-4357-817A-D58F31A95AC3Q37130763-424DED83-88D7-4959-A808-84594A3B5D4EQ37607514-6BF69CAC-D16D-40E8-881A-C501E1A42F90Q38195326-8F337B94-1B36-4F38-BC40-D47704603F22Q38840182-D60232C6-615E-4F69-8692-73585D6BB15DQ38845816-A52BB588-81C8-4E34-9696-C374CE1061CAQ40113232-565A7989-C4BB-4F71-958F-4B767B8EEBD6Q40739196-BD19A9E8-2119-4972-A305-65977A90FD5FQ40889243-994E9082-516B-4219-9BFD-ACEED97B7088Q41924035-4DBFCC96-D9EF-4A7E-81A7-BE5A41EBB191Q42204996-8001C74E-4308-4821-9018-BF47FB210468Q42265420-6D0BCBE7-09A8-40AB-959D-D1850B96E933
P2860
Progress on the research and development of inactivated EV71 whole-virus vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Progress on the research and development of inactivated EV71 whole-virus vaccines.
@en
Progress on the research and development of inactivated EV71 whole-virus vaccines.
@nl
type
label
Progress on the research and development of inactivated EV71 whole-virus vaccines.
@en
Progress on the research and development of inactivated EV71 whole-virus vaccines.
@nl
prefLabel
Progress on the research and development of inactivated EV71 whole-virus vaccines.
@en
Progress on the research and development of inactivated EV71 whole-virus vaccines.
@nl
P2093
P2860
P356
P1476
Progress on the research and development of inactivated EV71 whole-virus vaccines.
@en
P2093
Feng-Cai Zhu
Jing-Xin Li
Jun-Zhi Wang
Qun-Ying Mao
Yi-Ping Wang
Zheng-Lun Liang
P2860
P304
P356
10.4161/HV.24949
P577
2013-06-06T00:00:00Z
2013-08-01T00:00:00Z